Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly
The numbers aren’t all bad in biotech. But you’d be forgiven if you thought they were. And you’d be in good company. Once again, Chris Dokomajilar at DealForma has been checking the data for us ...
View ArticleEndpoints livestream: Curie.Bio CEO Zach Weinberg on China biotech competition
Today on Post-Hoc Live, we're talking about China — and how some in biotech want to make it harder for US companies to do deals there. The drug industry has turned to China for new molecules ...
View ArticleA state bill threatens to ban AI therapists, forcing health tech startups to...
AI therapists could soon be banned for the first time in the US under an Illinois bill, as mental health companies scramble to comply. The Wellness and Oversight for Psychological Resources Act forbids...
View ArticleDHL’s $700M+ expansion in UK and Ireland; Novo Nordisk’s quality testing site...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. DHL Supply Chain has invested £550 million ($748 million) to expand...
View ArticleSoleno's first wave of rare disease drug sales beats expectations
The first full quarter sales for Soleno Therapeutics’ rare disease drug Vykat XR are in, and they have exceeded investor forecasts. Soleno said Thursday morning that Vykat XR ...
View ArticleFor first time ever, FDA publishes drug rejection letters
In a historic first, the FDA on Thursday released about 200 novel and generic drug rejection letters, bucking the agency's former unwillingness to release the documents. But it's a small step ...
View ArticleAstraZeneca hands over opioid addiction pill to Eolas; TandemAI, Perpetual...
Plus, news about Pfizer and Astellas' Xtandi, BeOne Medicines, Biocytogen and Rhythm: Eolas Therapeutics takes opioid addiction pill from AstraZeneca: The biotech will assume full development rights ...
View ArticleAbbVie inks $700M deal with IGI for multiple myeloma trispecific antibody
AbbVie will spend $700 million upfront, plus future payments, on a trispecific antibody for blood cancer from IGI Therapeutics, adding to a slow but steady trend of deals for multi-target drugs. AbbVie...
View ArticleJazz taps current COO Renée Galá to replace CEO and co-founder Bruce Cozadd
Jazz Pharmaceuticals has named its next conductor. Renée Galá, the Dublin-based company’s current president and COO, will become CEO on August 11. She will succeed Jazz’s co-founder Bruce Cozadd, who...
View ArticleVarda raises $187M to advance drug manufacturing in space
Varda Space Industries has raised $187 million in a private funding round as the company leverages microgravity to overcome formulation issues that have long plagued drug development. Active...
View ArticleFDA approves Moderna's Covid shot for at-risk kids
The FDA on Thursday approved Moderna’s Covid-19 shot for kids six months through 11 years old who are at higher risk of severe disease, the latest move that fits the agency’s new vaccine framework. ...
View ArticleCentury Therapeutics lays off half of its staff, CFO departs as it narrows...
Cell therapy maker Century Therapeutics is cutting its workforce by around half in an effort to “right-size” the business as it homes in on therapeutic programs with the most potential. The...
View ArticleSally Susman waves goodbye to Pfizer; Xaira's new president and COO
→ Sally Susman will say goodbye to Pfizer at the end of 2025, capping an 18-year career leading the corporate affairs function at the global pharma giant. Susman played a big role in ...
View ArticleFDA hands Capricor a CRL for its Duchenne cell therapy
Capricor Therapeutics said on Friday it received a Complete Response Letter from the FDA for its lead cell therapy for Duchenne muscular dystrophy (DMD), citing the agency was not satisfied with its...
View ArticleAntag says it is confident ahead of 'imminent' Phase 1 obesity readout for...
Antag Therapeutics is taking an unusual, although not unknown, approach to obesity. Where drugs like Eli Lilly’s Zepbound and other compounds from Roche and Viking Therapeutics have mechanisms partly...
View ArticleManufacturing layoffs at Pacira; Oak Hill Bio’s Phase 1 Angelman data
Plus, news about Milestone Pharma: Pacira BioSciences cuts manufacturing staff: The company is laying off 71 employees at its Science Center Campus in San Diego, according to a California WARN notice....
View ArticleUK clears Bayer's hot flash treatment, marking first approval worldwide
The UK is the first in the world to approve Bayer's non-hormonal treatment for hot flashes, as the company awaits a decision from the FDA. The UK's Medicines and Healthcare products Regulatory Agency...
View ArticleFDA's Makary floats idea of fast-review vouchers in return for lower US prices
FDA Commissioner Marty Makary is calling for a seemingly unprecedented idea of dangling the promise of speedy reviews for experimental medicines in exchange for drugmakers vowing to lower US drug...
View ArticleFDA kicks off latest reauthorization of generic drug user fee legislation
FDA Commissioner Marty Makary on Friday opened up the first public meeting that kicked off negotiations for the next generic drug user fee agreement between the FDA and industry, explaining the...
View ArticleNovartis dealt a blow in patent fight to block Entresto generics
Novartis on Friday faced a setback in a key patent case as it fights to keep generic versions of its heart drug Entresto off the market. A federal district court in Delaware said Novartis failed ...
View ArticleRestrictions on Valneva’s chikungunya shot lifted in Europe
Valneva cleared a key safety hurdle for its chikungunya vaccine after European regulators removed a temporary restriction on its use in older adults. The European Medicines Agency announced Friday that...
View ArticleKaryopharm cuts 20% of staff as it looks at 'strategic alternatives' or...
Karyopharm Therapeutics is laying off 20% of its staff as it continues to search for cash to keep the lights on or "strategic alternatives" for its business. Friday's update, in a
View ArticleBiopharma’s highest-paid CEOs; John Carroll’s Q2 analysis; Merck to buy...
Welcome back to Endpoints Weekly! This week’s recap kicks off with the first installment of an Endpoints News series on pay in biopharma. Senior biopharma correspondent Andrew Dunn collected data on...
View Article